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INTRODUCTION 
Gas-filled microbubbles were originally developed as an intravascular contrast agent to enhance backscattering in ultrasound imaging. Microbubbles possess the ability 
to be an MR susceptibility contrast agent due to the induction of large local magnetic susceptibility differences by the gas-liquid interface. Feasibility of microbubbles 
as an MR pressure sensor, based on the susceptibility change caused by pressure-induced microbubble size change, has been explored through theoretical1 and phantom2 
studies. Gas-filled microbubbles have also been shown as an MR susceptibility contrast agent in vivo3. However, microbubble susceptibility effect is relatively weak 
when compared with other intravascular MR susceptibility contrast agents. By optimizing the microbubble size distribution and choice of shell coating material and 
core gas, it is possible to substantially enhance the microbubble susceptibility effects1 and reduce the dosage requirement for MR applications. In this study, we aim to 
demonstrate that microbubble susceptibility effects can be improved by embedding and entrapping iron oxide nanoparticles. 
METHODS 
Synthesis of iron oxide nanoparticles embedded albumin-coated microbubbles: Iron oxide nanoparticles embedded albumin-coated microbubbles (AMB) were 
produced by an adapted sonication method4. Briefly, 18 mg of monocrystalline iron oxide nanoparticles (MION; MGH) was added into a 5% solution of bovine serum 
albumin (10857, USB Corporation). The mixture was preheated to about 70oC and sonicated under aseptic conditions using an ultrasound frequency of 20 kHz. 
Synthesis of iron oxide nanoparticles entrapped polymeric microbubbles: Iron oxide nanoparticles entrapped polymeric microbubbles (polymeric MB) were produced 
by an adapted double emulsion method5. Briefly, 0.5g poly(D,L-lactide-co-glycolic acid 50:50, PLGA; Sigma) was dissolved in 10 mL of ethyl acetate (Sigma). 1 mL 
of MION solution (1.164mg/mL) was added to the polymer solution and probe sonicated for 30 s. The W/O emulsion was then poured into a 5% poly(vinyl alcohol) 
(PVA; Sigma) solution and homogenized for 5 min. The double (W/O)/W emulsion was then poured into a 2% isopropyl alcohol (Sigma) and stirred at room 
temperature for 1 hour. The capsules were collected by centrifugation, washed once with deionized water, centrifuged at 15°C for 5 min. at 3000g and the supernatant 
discarded. The capsules were then washed three times with hexane (Sigma). The capsules were frozen in a -80°C freezer and lyophilized using a freeze dryer to fully 
dry the capsules and sublime the encapsulated water. MRI and Data Analysis: All MRI experiments were performed on a 7 T Bruker MRI scanner. Microbubble 
phantom study was performed with 38-mm quadrature resonator for RF transmission and receiving. AMB were diluted from a well-mixed microbubble suspension to 
4% volume fraction with the addition of saline, while polymeric MB were prepared by adding saline of 2 mL to 50 mg of the lyophilized powder. The microbubbles 
were then placed in separate 2-mL cylindrical phantom tubes. Each phantom tube was slowly warmed to room temperature and gently mixed for 2 min outside the 
magnet prior to MR measurements. To ensure uniform suspension of microbubbles, the phantom was then continuously stirred by rotation inside the magnet. It was 
then arrested in horizontal position immediately before the start of MR acquisition sequence. Apparent transverse relaxation rate enhancement (ΔR2*) was measured by 
acquiring multi-echo gradient-echo (GE) signals continuously without phase encoding for 2 min from an axial 1-mm slice at middle of the phantom. The measurement 
was repeated six times for each microbubble phantom. The parameters were TR = 1000 ms, TE = 3.5, 7, 10.5, 14, 17.5, 21, 24.5, 28 ms, flip angle = 30º and NEX = 1. 
Phantom R2* values were computed by monoexponential fitting of the peak magnitudes of the multi-echo GE signals using a software toolkit developed in MATLAB 
(MathWorks). Initially, there was a uniform suspension of microbubbles. As GE signals were acquired, microbubbles started to migrate upward; therefore, in the final 
state the microbubbles aggregated in the upper part of the tube. Microbubble induced ∆R2* was then calculated as the difference between R2* in the initial state and that 
in the final state. To demonstrate that MION were embedded and entrapped, R2* was measured before and after cavitation, which was performed by applying ultrasound 
of frequency 40 kHz. R2* maps of the suspending solutions were acquired before and after cavitation with multiple gradient echo sequences. In vivo Demonstration: 
Normal SD rats (~200-250 g) were injected intravenously with 0.2 mL of microbubble suspension (~4% volume fraction; N = 1 for AMB with MION and N = 1 for 
polymeric MB with MION) at a rate of 1.2 mL/min to avoid possible microbubble destruction due to high pressure and shear stress under femoral vein catheterization. 
Dynamic susceptibility weighted liver MRI was performed with respiratory-gated single-shot GE-EPI sequence under inhaled isoflurane anaesthesia using TR ≈ 1000 
ms, TE = 10 ms, FA = 90º, FOV = 50 mm × 50 mm, slice thickness = 2 mm, acquisition matrix = 64 × 64, and NEX = 1. 
RESULTS AND DISCUSSIONS 
Values of R2* were plotted against time in Figure 1 for 
different microbubbles. As GE signals were acquired, 
microbubbles started to migrate upward; therefore, in 
the final state values of R2* were due to the suspending 
solution. The different amounts of free MION in the 
suspended solution accounted for the difference in the 
R2* of the suspending solution. Microbubble induced 
∆R2* of different microbubbles were depicted in Figure 
2. The MION embedded and entrapped would enhance 
the susceptibility effect and increased the values of ∆R2* 
as MION would float along with the microbubbles, 
resulting a larger ∆R2* values. Suspending solution R2* 
for AMB without and with MION after cavitation were 
found to be increased by 1.41 s-1 and 23.91 s-1 
respectively. Similarly, suspending solution R2* for polymeric MB without and with MION after cavitation were found to be 
increased by 1.52 s-1 and 75.84 s-1 respectively. These substantial differences for microbubbles with MION demonstrate that 
there were more MION in the suspending solution after cavitation; suggesting that embedded and entrapped MION were 
released into suspending solution after the microbubble cavitation. Transmission electron microscopy was done on AMB with 
MION and depicted in Figure 3. MION as dark dots (red arrows) were observed on the shells of AMB, validating MION was 
embedded onto shells of AMB. Nevertheless, small amount of free MION was also observed in suspending solution (green 
arrow). Figure 4(a) shows one of the preinjection GE-EPI T2*-weighted images, while (b) shows the postinjection GE-EPI T2*-
weighted image with the maximum susceptibility contrast for polymeric MB with MION injection. Figure 5 depicts the T2*-
weighted signal time course during polymer MB with MION injection with ROI selected from homogeneous liver region 
(indicated in Figure 4(a)). Similar signal time course was also observed during AMB with MION injection. The T2*-weighted 
signals after microbubble injection did not return to the preinjection baseline, this may be caused by accumulation of released 
MION in Kupffer cells after in vivo microbubble clearance. 
CONCLUSIONS  
In this study, we demonstrated, for the first time, that embedding iron oxide nanoparticles onto shells of albumin-coated 
microbubbles and entrapping iron oxide nanoparticles in polymeric microbubbles is feasible. Work is currently underway to 
characterize the in vivo susceptibility effects of these microbubbles. With such approach, microbubble susceptibility can be 
significantly enhanced, so that microbubbles can be monitored with high sensitivity and low concentrations under MRI.  
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Figure 1 Values of R2* were plotted 
against time for different microbubbles. 
Figure 2 Microbubble induced ∆R2* of 
different microbubbles. The error bars 
represent one standard deviation. 
Figure 3 Transmission electron 
microsgraph shows MION was 
embedded onto shells of AMB. 
 
Figure 4 GE-EPI T2*-weighted image for  
polymeric MB w/ MION (a) preinjection 
image and (b) postinjection with the 
maximum susceptibility contrast. 
Figure 5 T2*-weighted signal time course 
in a homogenous liver region during 
polymeric MB w/ MION injection.  
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